ACU NE1
Alternative Names: ACU-NE1Latest Information Update: 05 Sep 2023
At a glance
- Originator Accuitis
- Class Antidementias; Antiparkinsonians
- Mechanism of Action Glycogen synthase kinase 3 beta inhibitors; SIRT3 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Cognition disorders; Dementia; Parkinson's disease
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route) (Accuitis pipeline, September 2023)
- 05 Sep 2023 Discontinued - Preclinical for Cognition disorders in USA (unspecified route) (Accuitis pipeline, September 2023)
- 05 Sep 2023 Discontinued - Preclinical for Dementia in USA (unspecified route) (Accuitis pipeline, September 2023)